Allitinib

Allitinib (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. Allitinib also inhibits ErbB4 with an IC50 of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity[1].

Product Specifications

CAS Number

[897383-62-9]

Product Name Alternative

AST-1306; ALS 1306

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ast-1306.html

Purity

99.36

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC=CC(COC2=C(Cl)C=C(NC3=NC=NC4=C3C=C(NC(C=C)=O)C=C4)C=C2)=C1

Molecular Formula

C24H18ClFN4O2

Molecular Weight

448.88

Precautions

H302, H315, H319

References & Citations

[1]Xie H, Lin L, Tong L et al. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6 (7) :e21487.